カテゴリ： Allied Market Research, 世界, 医療/バイオ

ハンチントン病治療のグローバル市場（2021〜2031）：承認薬、適応外薬

■ 英語タイトル：Huntington’s Disease Treatment Market By Drug type (Approved drugs, Offlabel drugs), By Age (Below 50 years, Above 50 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23JN016）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23JN016
■ 発行日：2022年9月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：301
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[ハンチントン病治療のグローバル市場（2021〜2031）：承認薬、適応外薬]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本調査資料では、2021年に315.18百万ドルであった世界のハンチントン病治療市場規模が、2031年までに707.5百万ドルに到達し、2022年から2031年の間に年平均8.4%で拡大すると予測しています。本資料は、ハンチントン病治療の世界市場について総合的に調査・分析を行い、イントロダクション、エグゼクティブサマリー、市場概要、医薬品別（承認薬、適応外薬）分析、年齢別（50歳以下、50歳以上）分析、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などの項目を以下の構成でまとめております。本資料は、Prilenia Therapeutics、som biotech、Bausch Health Companies Inc.、Teva Pharmaceutical Industries Ltd.、Novartis AG、Lupin、UniQure、Hikma Pharmaceuticals plcなどの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界のハンチントン病治療市場規模：医薬品別
-承認薬における市場規模
-適応外薬における市場規模
・世界のハンチントン病治療市場規模：年齢別
-50歳以下における市場規模
-50歳以上における市場規模
・世界のハンチントン病治療市場規模：流通チャネル別
-病院薬局チャネルの市場規模
-ドラッグストア・小売薬局チャネルの市場規模
-オンライン薬局チャネルの市場規模
・世界のハンチントン病治療市場規模：地域別
- 北米のハンチントン病治療市場規模
- ヨーロッパのハンチントン病治療市場規模
- アジア太平洋のハンチントン病治療市場規模
- 中南米・中東・アフリカのハンチントン病治療市場規模
・企業状況
・企業情報

ハンチントン病は、脳神経細胞の破壊が進行するまれな遺伝病です。症状が現れる速度は人によって異なります。運動能力の変化が最初に現れ、その後に抑うつ症状が現れる人もいます。気分の変化や奇妙な行動は、しばしば早期警告の指標となります。ハンチントン病は運動能力、認知能力、心理的な問題を引き起こし、機能的能力に大きな影響を与えます。ハンチントン病の症状を管理するのに役立つ薬があります。現在のところ、ハンチントン病患者に対する疾患修飾薬は承認されていません。

ハンチントン病治療市場の成長を促進する主な要因は、有病人口の増加と、ハンチントン病に関連する症状をコントロールするための高度な薬剤タイプに対する需要の増加です。さらに、強力な新薬パイプラインが市場の主要なトレンドであり、予測期間中の成長を促進すると期待されています。

患者数の増加が薬剤需要の増加につながるため、患者数の大幅な増加は市場の主要な要因の1つです。例えば、BJM Journal誌が発表した研究論文によると、英国ではHDの有病率が高いとのことです。このようなHDの高い有病率は、その治療においてより多くの工夫と対応力を必要とします。したがって、このような症例数の多さは、ハンチントン病治療市場の成長を後押しすると予想されます。
また、過去10年間における遺伝子治療や幹細胞治療のような先進的な治療に対する需要の急増が、市場の成長を後押ししています。

さらに、創薬および薬剤開発における研究開発投資の増加は、市場成長にとって有利な機会となっています。しかし、薬剤開発プロセスに関連する合併症が市場成長の妨げになると予想されます。
世界のハンチントン病治療市場は、薬剤の種類、年齢、流通チャネル、地域によって区分されます。薬剤タイプ別では、市場は承認薬と適応外薬に分類されます。承認薬セグメントはさらにテトラベナジンとドイテトラベナジンに分類されます。年齢別では、50歳未満と50歳以上に分類されます。流通チャネル別では、病院薬局、ドラッグストア・小売薬局、オンライン薬局に分類されます。地域別では、北米、欧州、アジア太平洋、中南米・中東・アフリカ（LAMEA）に市場を分けて分析しています。

本レポートに掲載されている主要企業は、Annexon Biosciences、Bausch Health Companies Inc、Dr.Reddy’s Laboratories Ltd、Eli Lilly And Company、Hikma Pharmaceuticals PLC、Lupin、Medesis pharma SA、Mitochon Pharmaceuticals、Neurocrine bioscience Inc、Novartis、PTC Therapeutics, Inc、SOM Biotech、Sun Pharmaceuticals、Teva Pharmaceuticals Industries Ltd、UniQure、Vaccinex, Inc.です。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までのハンチントン病治療市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、ハンチントン病治療市場の有力な市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・ハンチントン病治療市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別および世界のハンチントン病治療市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
薬剤タイプ別
承認薬
適応外薬

年齢別
50歳未満
50歳以上

流通チャネル別
病院薬局
ドラッグストア・小売薬局
オンライン薬局

地域別
・北米
アメリカ
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Prilenia Therapeutics
som biotech
Bausch Health Companies Inc.
Teva Pharmaceutical Industries Ltd.
Novartis AG
Lupin
UniQure
Hikma Pharmaceuticals plc
Annexon Biosciences
Dr. Reddy’s Laboratories Ltd.
Neurocrine Biosciences
PTC Therapeutics
AOP Health
Medesis Pharma SA
Mitochon Pharmaceuticals
Sun Pharmaceuticals Industries Ltd.
Vaccinex, Inc

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Approved drugs
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.2.4 Approved drugs Huntington’s Disease Treatment Market by Type
4.2.4.1 Tetrabenazine Market size and forecast, by region
4.2.4.2 Deutetrabenazine Market size and forecast, by region
4.3 Offlabel drugs
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
CHAPTER 5: HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE
5.1 Overview
5.1.1 Market size and forecast
5.2 Below 50 years
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Above 50 years
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Drug store and retail pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Online pharmacies
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: HUNTINGTON’S DISEASE TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug type
7.2.2.1 North America Approved drugs Huntington’s Disease Treatment Market by Type
7.2.3 North America Market size and forecast, by Age
7.2.4 North America Market size and forecast, by Distribution channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Drug type
7.2.5.1.3 Market size and forecast, by Age
7.2.5.1.4 Market size and forecast, by Distribution channel
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Drug type
7.2.5.2.3 Market size and forecast, by Age
7.2.5.2.4 Market size and forecast, by Distribution channel
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Drug type
7.2.5.3.3 Market size and forecast, by Age
7.2.5.3.4 Market size and forecast, by Distribution channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug type
7.3.2.1 Europe Approved drugs Huntington’s Disease Treatment Market by Type
7.3.3 Europe Market size and forecast, by Age
7.3.4 Europe Market size and forecast, by Distribution channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Drug type
7.3.5.1.3 Market size and forecast, by Age
7.3.5.1.4 Market size and forecast, by Distribution channel
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Drug type
7.3.5.2.3 Market size and forecast, by Age
7.3.5.2.4 Market size and forecast, by Distribution channel
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Drug type
7.3.5.3.3 Market size and forecast, by Age
7.3.5.3.4 Market size and forecast, by Distribution channel
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Drug type
7.3.5.4.3 Market size and forecast, by Age
7.3.5.4.4 Market size and forecast, by Distribution channel
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Drug type
7.3.5.5.3 Market size and forecast, by Age
7.3.5.5.4 Market size and forecast, by Distribution channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Drug type
7.3.5.6.3 Market size and forecast, by Age
7.3.5.6.4 Market size and forecast, by Distribution channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug type
7.4.2.1 Asia-Pacific Approved drugs Huntington’s Disease Treatment Market by Type
7.4.3 Asia-Pacific Market size and forecast, by Age
7.4.4 Asia-Pacific Market size and forecast, by Distribution channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Drug type
7.4.5.1.3 Market size and forecast, by Age
7.4.5.1.4 Market size and forecast, by Distribution channel
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Drug type
7.4.5.2.3 Market size and forecast, by Age
7.4.5.2.4 Market size and forecast, by Distribution channel
7.4.5.3 India
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Drug type
7.4.5.3.3 Market size and forecast, by Age
7.4.5.3.4 Market size and forecast, by Distribution channel
7.4.5.4 Australia
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Drug type
7.4.5.4.3 Market size and forecast, by Age
7.4.5.4.4 Market size and forecast, by Distribution channel
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Drug type
7.4.5.5.3 Market size and forecast, by Age
7.4.5.5.4 Market size and forecast, by Distribution channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Drug type
7.4.5.6.3 Market size and forecast, by Age
7.4.5.6.4 Market size and forecast, by Distribution channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug type
7.5.2.1 LAMEA Approved drugs Huntington’s Disease Treatment Market by Type
7.5.3 LAMEA Market size and forecast, by Age
7.5.4 LAMEA Market size and forecast, by Distribution channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Drug type
7.5.5.1.3 Market size and forecast, by Age
7.5.5.1.4 Market size and forecast, by Distribution channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Drug type
7.5.5.2.3 Market size and forecast, by Age
7.5.5.2.4 Market size and forecast, by Distribution channel
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Drug type
7.5.5.3.3 Market size and forecast, by Age
7.5.5.3.4 Market size and forecast, by Distribution channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Drug type
7.5.5.4.3 Market size and forecast, by Age
7.5.5.4.4 Market size and forecast, by Distribution channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Prilenia Therapeutics
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 som biotech
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Bausch Health Companies Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Teva Pharmaceutical Industries Ltd.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Novartis AG
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Lupin
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 UniQure
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Hikma Pharmaceuticals plc
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Annexon Biosciences
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Dr. Reddy’s Laboratories Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Neurocrine Biosciences
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 PTC Therapeutics
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 AOP Health
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Medesis Pharma SA
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Mitochon Pharmaceuticals
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
9.16 Sun Pharmaceuticals Industries Ltd.
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Operating business segments
9.16.4 Product portfolio
9.16.5 Business performance
9.16.6 Key strategic moves and developments
9.17 Vaccinex, Inc
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Operating business segments
9.17.4 Product portfolio
9.17.5 Business performance
9.17.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 2. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR APPROVED DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR APPROVED DRUGS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. GLOBAL APPROVED DRUGS HUNTINGTON’S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 5. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR TETRABENAZINE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 6. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR DEUTETRABENAZINE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 7. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR OFFLABEL DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 8. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR OFFLABEL DRUGS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 9. GLOBAL HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 10. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR BELOW 50 YEARS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR BELOW 50 YEARS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 12. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR ABOVE 50 YEARS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR ABOVE 50 YEARS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 14. GLOBAL HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 15. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 17. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 18. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 19. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 20. HUNTINGTON’S DISEASE TREATMENT MARKET, FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 21. HUNTINGTON’S DISEASE TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 22. NORTH AMERICA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 23. NORTH AMERICA APPROVED DRUGS HUNTINGTON’S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 24. NORTH AMERICA HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 25. NORTH AMERICA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 26. NORTH AMERICA HUNTINGTON’S DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 27. U.S. HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 28. U.S. HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 29. U.S. HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 30. CANADA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 31. CANADA HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. CANADA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 33. MEXICO HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 34. MEXICO HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 35. MEXICO HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 36. EUROPE HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 37. EUROPE APPROVED DRUGS HUNTINGTON’S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 38. EUROPE HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 39. EUROPE HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 40. EUROPE HUNTINGTON’S DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 41. GERMANY HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 42. GERMANY HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 43. GERMANY HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 44. FRANCE HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 45. FRANCE HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 46. FRANCE HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 47. UK HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 48. UK HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 49. UK HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 50. ITALY HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 51. ITALY HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 52. ITALY HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 53. SPAIN HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 54. SPAIN HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 55. SPAIN HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 56. REST OF EUROPE HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 57. REST OF EUROPE HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 58. REST OF EUROPE HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 59. ASIA-PACIFIC HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. ASIA-PACIFIC APPROVED DRUGS HUNTINGTON’S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 61. ASIA-PACIFIC HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 62. ASIA-PACIFIC HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 63. ASIA-PACIFIC HUNTINGTON’S DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 64. JAPAN HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 65. JAPAN HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 66. JAPAN HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 67. CHINA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 68. CHINA HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 69. CHINA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 70. INDIA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 71. INDIA HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 72. INDIA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 73. AUSTRALIA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 74. AUSTRALIA HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 75. AUSTRALIA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 76. SOUTH KOREA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 77. SOUTH KOREA HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 78. SOUTH KOREA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 79. REST OF ASIA-PACIFIC HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 80. REST OF ASIA-PACIFIC HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 81. REST OF ASIA-PACIFIC HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 82. LAMEA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 83. LAMEA APPROVED DRUGS HUNTINGTON’S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 84. LAMEA HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 85. LAMEA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 86. LAMEA HUNTINGTON’S DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 87. BRAZIL HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 88. BRAZIL HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 89. BRAZIL HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 90. SAUDI ARABIA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 91. SAUDI ARABIA HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 92. SAUDI ARABIA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 93. SOUTH AFRICA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 94. SOUTH AFRICA HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 95. SOUTH AFRICA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 96. REST OF LAMEA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 97. REST OF LAMEA HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 98. REST OF LAMEA HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 99.PRILENIA THERAPEUTICS: COMPANY SNAPSHOT
TABLE 100.PRILENIA THERAPEUTICS: OPERATING SEGMENTS
TABLE 101.PRILENIA THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 102.PRILENIA THERAPEUTICS: NET SALES,
TABLE 103.PRILENIA THERAPEUTICS: KEY STRATERGIES
TABLE 104.SOM BIOTECH: COMPANY SNAPSHOT
TABLE 105.SOM BIOTECH: OPERATING SEGMENTS
TABLE 106.SOM BIOTECH: PRODUCT PORTFOLIO
TABLE 107.SOM BIOTECH: NET SALES,
TABLE 108.SOM BIOTECH: KEY STRATERGIES
TABLE 109.BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 110.BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS
TABLE 111.BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 112.BAUSCH HEALTH COMPANIES INC.: NET SALES,
TABLE 113.BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES
TABLE 114.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 115.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 116.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 117.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
TABLE 118.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 119.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 120.NOVARTIS AG: OPERATING SEGMENTS
TABLE 121.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 122.NOVARTIS AG: NET SALES,
TABLE 123.NOVARTIS AG: KEY STRATERGIES
TABLE 124.LUPIN: COMPANY SNAPSHOT
TABLE 125.LUPIN: OPERATING SEGMENTS
TABLE 126.LUPIN: PRODUCT PORTFOLIO
TABLE 127.LUPIN: NET SALES,
TABLE 128.LUPIN: KEY STRATERGIES
TABLE 129.UNIQURE: COMPANY SNAPSHOT
TABLE 130.UNIQURE: OPERATING SEGMENTS
TABLE 131.UNIQURE: PRODUCT PORTFOLIO
TABLE 132.UNIQURE: NET SALES,
TABLE 133.UNIQURE: KEY STRATERGIES
TABLE 134.HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT
TABLE 135.HIKMA PHARMACEUTICALS PLC: OPERATING SEGMENTS
TABLE 136.HIKMA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
TABLE 137.HIKMA PHARMACEUTICALS PLC: NET SALES,
TABLE 138.HIKMA PHARMACEUTICALS PLC: KEY STRATERGIES
TABLE 139.ANNEXON BIOSCIENCES: COMPANY SNAPSHOT
TABLE 140.ANNEXON BIOSCIENCES: OPERATING SEGMENTS
TABLE 141.ANNEXON BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 142.ANNEXON BIOSCIENCES: NET SALES,
TABLE 143.ANNEXON BIOSCIENCES: KEY STRATERGIES
TABLE 144.DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 145.DR. REDDY’S LABORATORIES LTD.: OPERATING SEGMENTS
TABLE 146.DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 147.DR. REDDY’S LABORATORIES LTD.: NET SALES,
TABLE 148.DR. REDDY’S LABORATORIES LTD.: KEY STRATERGIES
TABLE 149.NEUROCRINE BIOSCIENCES: COMPANY SNAPSHOT
TABLE 150.NEUROCRINE BIOSCIENCES: OPERATING SEGMENTS
TABLE 151.NEUROCRINE BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 152.NEUROCRINE BIOSCIENCES: NET SALES,
TABLE 153.NEUROCRINE BIOSCIENCES: KEY STRATERGIES
TABLE 154.PTC THERAPEUTICS: COMPANY SNAPSHOT
TABLE 155.PTC THERAPEUTICS: OPERATING SEGMENTS
TABLE 156.PTC THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 157.PTC THERAPEUTICS: NET SALES,
TABLE 158.PTC THERAPEUTICS: KEY STRATERGIES
TABLE 159.AOP HEALTH: COMPANY SNAPSHOT
TABLE 160.AOP HEALTH: OPERATING SEGMENTS
TABLE 161.AOP HEALTH: PRODUCT PORTFOLIO
TABLE 162.AOP HEALTH: NET SALES,
TABLE 163.AOP HEALTH: KEY STRATERGIES
TABLE 164.MEDESIS PHARMA SA: COMPANY SNAPSHOT
TABLE 165.MEDESIS PHARMA SA: OPERATING SEGMENTS
TABLE 166.MEDESIS PHARMA SA: PRODUCT PORTFOLIO
TABLE 167.MEDESIS PHARMA SA: NET SALES,
TABLE 168.MEDESIS PHARMA SA: KEY STRATERGIES
TABLE 169.MITOCHON PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 170.MITOCHON PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 171.MITOCHON PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 172.MITOCHON PHARMACEUTICALS: NET SALES,
TABLE 173.MITOCHON PHARMACEUTICALS: KEY STRATERGIES
TABLE 174.SUN PHARMACEUTICALS INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 175.SUN PHARMACEUTICALS INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 176.SUN PHARMACEUTICALS INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 177.SUN PHARMACEUTICALS INDUSTRIES LTD.: NET SALES,
TABLE 178.SUN PHARMACEUTICALS INDUSTRIES LTD.: KEY STRATERGIES
TABLE 179.VACCINEX, INC: COMPANY SNAPSHOT
TABLE 180.VACCINEX, INC: OPERATING SEGMENTS
TABLE 181.VACCINEX, INC: PRODUCT PORTFOLIO
TABLE 182.VACCINEX, INC: NET SALES,
TABLE 183.VACCINEX, INC: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 抗コクシジウム薬のグローバル市場（2021〜2031）：イオノフォア、合成薬
  • ハンチントン病治療のグローバル市場：対症治療、疾患修飾療法
  • ブラストミセス症のグローバル市場（2021〜2031）：錠剤、軟膏、粉末、液体
  • 治療薬物モニタリング（TDM）のグローバル市場（2021-2031）：消耗品、装置
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23JN016 )"ハンチントン病治療のグローバル市場（2021〜2031）：承認薬、適応外薬" (英文：Huntington’s Disease Treatment Market By Drug type (Approved drugs, Offlabel drugs), By Age (Below 50 years, Above 50 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。